December 2013

Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared with doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas

The genomic instability inherent in serous ovarian cancer poses treatment challenges, but it also represents a target that can be exploited through the use of PARP inhibitors

The criteria that are presently used to determine whether patients with non-small cell lung cancer (NSCLC) may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug, researchers report.

New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression- free survival (PFS) than placebo and exemestane in several previously unstudied patient subgroups.

Both men and women report a significant decline in sexual satisfaction after hematopoietic cell transplantation (HCT) that is sustained at 3-year follow-up

An analysis of cancer care coordination over the last 30 years shows that the process offers many benefits to oncology patients, including fewer hospitalizations and visits to emergency departments and increased patient satisfaction with care.

In 2012, the American Society of Clinical Oncology (ASCO) recommended routinely offering palliative care to patients with metastatic cancer and uncontrolled symptoms to improve symptom control and quality of life and reduce caregiver burden.

As more immunotherapies move from the bench to the bedside, oncology nurses need to develop a thorough understanding of how these treatments work, as well as how their adverse event profiles differ from those typically seen with traditional cytotoxic regimens

Cancer-related lymphedema can result from the cancer or its treatment. It is an accumulation of protein-rich fluid in an interstitial space which may be the result of surgical resection, lymph node dissection, or radiation therapy

The "renaissance in immunology" is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand

The results emerging from the PD-1/PD-L1 trials mark a major step forward, noted Rajni Kannan, MN, RN, ANP, in a recent interview on the implications of this research for multiple cancers, including melanoma

The FDA's approval in 2010 of sipuleucel-T (Provenge) marked a milestone in the treatment of men with advanced prostate cancer and ushered in an exciting new immunotherapeutic treatment approach.

In 2010, Smilow Cancer Hospital (SCH) at Yale New Haven and Yale Cancer Center (YCC) transitioned from a multisite cancer care delivery system that was both university- and hospitalbased to a new, state-of-the-art, 14-story comprehensive cancer center building.

Dermatologic adverse events (AEs) associated with anticancer therapies can be complex and are best managed with a proactive and holistic approach-one that takes into account not only the physical demands of the regimen itself, but also the many challenges that patients often face involving treatment adherence, quality of life, and psychosocial concerns.

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castration-resistant prostate cancer.